Results 21 to 30 of about 24,414 (214)

Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Beyond Lipids: The Role in Oxidative Stress and Thrombosis

Antioxidants, 2022
Proprotein convertase subtilisin/kexin type 9 (PCSK9), mainly secreted in the liver, is a key regulator of cholesterol homeostasis inducing LDL receptors’ degradation.
V. Cammisotto, F. Baratta, P. Simeone, C. Barale, E. Lupia, Gioacchini Galardo, F. Santilli, I. Russo, P. Pignatelli   +8 more
semanticscholar   +1 more source

Proprotein convertase subtilisin/kexin type 9 is a psoriasis-susceptibility locus that is negatively related to IL36G

JCI Insight, 2022
Proprotein convertase subtilisin/kexin type-9 (PCSK9) is a posttranslational regulator of the LDL receptor (LDLR). Recent studies have proposed a role for PCSK9 in regulating immune responses.
A. Merleev, A. Ji-Xu, A. Toussi, L. Tsoi, S. Le, G. Luxardi, X. Xing, R. Wasikowski, W. Liakos, M. Brüggen, James T. Elder, I. Adamopoulos, Y. Izumiya, Annie Riera-Leal, Qinyuan Li, N. Kuzminykh, Amanda R Kirane, A. Marusina, J. Gudjonsson, E. Maverakis   +19 more
semanticscholar   +1 more source

PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Triggers Vascular Smooth Muscle Cell Senescence and Apoptosis: Implication of Its Direct Role in Degenerative Vascular Disease

Arteriosclerosis, Thrombosis and Vascular Biology, 2021
Supplemental Digital Content is available in the text. Objective: PCSK9 (proprotein convertase subtilisin/kexin type 9) plays a critical role in cholesterol metabolism via the PCSK9–LDLR (low-density lipoprotein receptor) axis in the liver; however ...
Yanan Guo, Zhi-Bin Tang, Binjie Yan, H. Yin, S. Tai, Juan Peng, Yuting Cui, Y. Gui, D. Belke, Shenghua Zhou, Xi-Long Zheng   +10 more
semanticscholar   +1 more source

Proprotein Convertase Subtilisin/Kexin Type 9 Promotes Gastric Cancer Metastasis and Suppresses Apoptosis by Facilitating MAPK Signaling Pathway Through HSP70 Up-Regulation

Frontiers in Oncology, 2021
Objective To examine the effect of proprotein convertase subtilisin/kexin type 9 (PCSK9) on gastric cancer (GC) progression and prognosis, and to explore the underlying mechanism.
Bei-li Xu, Shuyu Li, Yong Fang, Y. Zou, Dongqiang Song, Shuncai Zhang, Yu Cai   +6 more
semanticscholar   +1 more source

New Insight Into Metformin-Induced Cholesterol-Lowering Effect Crosstalk Between Glucose and Cholesterol Homeostasis via ChREBP (Carbohydrate-Responsive Element-Binding Protein)-Mediated PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Regulation.

Arteriosclerosis, Thrombosis and Vascular Biology, 2021
OBJECTIVE Metformin, a first-line drug for treating individuals with type 2 diabetes, exerts beneficial effects on cholesterol-lowering, yet its precise mechanism has not been established.
Die Hu, Yanhong Guo, R. Wu, Tiannan Shao, Junke Long, Bilian Yu, Huilun Wang, Yonghong Luo, Haocheng Lu, Jifeng Zhang, Y. E. Chen, Daoquan Peng   +11 more
semanticscholar   +1 more source

Lipid lowering with bempedoic acid added to a proprotein convertase subtilisin/kexin type 9 inhibitor therapy: A randomized, controlled trial.

Journal of Clinical Lipidology, 2021
BACKGROUND Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9is) lower low-density lipoprotein cholesterol (LDL-C) in patients with hypercholesterolemia. However, some patients receiving PCSK9i therapy might require additional lipid-lowering
J. Rubino, D. Macdougall, L. Sterling, S. Kelly, J. Mckenney, N. Lalwani   +5 more
semanticscholar   +1 more source

Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors Reduce Platelet Activation Modulating ox-LDL Pathways

International Journal of Molecular Sciences, 2021
Background: Proprotein convertase subtilisin kexin type 9 inhibitors (PCSK9i) lower LDL-cholesterol and slow atherosclerosis preventing cardiovascular events.
V. Cammisotto, F. Baratta, Valentina Castellani, S. Bartimoccia, C. Nocella, L. D’Erasmo, N. Cocomello, C. Barale, Roberto Scicali, A. Di Pino, S. Piro, M. del Ben, M. Arca, I. Russo, F. Purrello, R. Carnevale, F. Violi, D. Pastori, P. Pignatelli   +18 more
semanticscholar   +1 more source

Effects of proprotein convertase subtilisin kexin type 9 modulation in human pancreatic beta cells function.

Atherosclerosis, 2021
BACKGROUND AND AIMS Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) is an endogenous inhibitor of the LDL receptor (LDLR). Mendelian randomization studies suggest that PCSK9 deficiency increases diabetes risk, but the underlying mechanisms remain ...
S. Ramin-Mangata, A. Thedrez, B. Nativel, N. Diotel, V. Blanchard, Matthieu Wargny, A. Aguesse, S. Billon-Crossouard, C. Vindis, C. Le May, P. Hulin, M. Armanet, V. Gmyr, F. Pattou, Mikaël Croyal, O. Meilhac, E. Nobécourt, B. Cariou, G. Lambert   +18 more
semanticscholar   +1 more source

Discovery and SAR analysis of phenylbenzo[d][1,3]dioxole-based proprotein convertase subtilisin/kexin type 9 inhibitors

Journal of Enzyme Inhibition and Medicinal Chemistry, 2022
Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a novel therapeutic target for the development of cholesterol-lowering drugs.
Fahui Li, Lihui Zhang, Jinhong Feng, Lei Zhang   +3 more
doaj   +1 more source

Lipid Parameters and Proprotein Convertase Subtilisin/Kexin Type 9 in Healthy Lebanese Adults

Metabolites, 2022
Background: High levels of non-HDL cholesterol (non-HDL-C), triglycerides (TG), lipoprotein (a) (Lp(a)), and Proprotein convertase subtilisin/kexin type 9 (PCSK9) as well as low levels of HDL-C are strongly associated with cardiovascular disease (CVD ...
Marie-Hélène Gannagé-Yared, Elie Naous, Anis Al Achkar, Wadih Issa, Ghassan Sleilaty, Vanda Barakett-Hamade, Marianne Abifadel   +6 more
doaj   +1 more source